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heriac Found? Nitric
xide-Aspirin and the
earch for the Universal Cure*
ichard I. Levin, MD, FACC, FACP, FAHA
ew York, New York
n the second century of this era, a consul of Rome
ntroduced his doctor, Claudius Galenus of Pergamum, to
mperor Marcus Aurelius. They got along famously, and
alen became the court physician. Renowned for his public
ivisections, which allowed startling advances in the fields of
natomy and physiology, Galen joined a band of both
otable and notorious doctors on a 4,000-year-old quest for
he universal cure. Galen’s theriac (loosely from the Greek
or animal flesh), or antidote, was a grand version of the
ompounded drug of the day. It was the antidote to
othing, but presaging Jenner’s invention of immunother-
py by prior exposure to a related antigen, and among its 70
r more ingredients, it contained snake meat for protection
gainst snakebite. Its active ingredients were opium and the
nest of white Falernian wines from the central slopes north
f Naples (1). No cure-all, but after brewing for 40 days, it
as imbibed with gusto.
See page 635
In this issue of the Journal, Fiorucci et al. (2) embellish
heir interesting story and tell us of the clinical relevance
f a modern, actual theriac called nitric oxide (NO)-
spirin (NCX-4016). Like Galen’s, it is a designer drug
hose two active ingredients, the molecules of the year of
897 and 1992 (3), dissociate from the parent molecule to
xert their effects (Fig. 1). Acetylsalicylic acid, or aspirin,
as probably first synthesized by Gerhardt in 1853,
esynthesized in a purer form by Kraut in 1869, and then
discovered” by Hoffmann of Friedrich Bayer & Co. in
897 (4). Mimicking other legends of rational drug
esign, what it does is not nearly what it was supposed to
o. Salicylic acid, an anti-inflammatory in its own right
5), is highly toxic to the gastrointestinal tract, and those
uropean chemists of the late 19th century used acety-
ation as a means to buffer the parent compound. How-
ver, the remarkable activity of aspirin against the leading
auses of death in the West, in both the prevention of
hrombotic vascular events (6) and the chemoprevention
f cancer (7), resides not in the salicylate, but in the acetyl
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Leon H. Charney Division of Cardiology, New York University Schoolef Medicine, New York, New York.roup. Acetylation of the catalytic sites of the first
nzyme in the prostaglandin cascade, either cyclooxygen-
se (prostaglandin H synthase)-1 at Ser529 or its isozyme
yclooxygenase-2 at Ser516, shuts down the prostanoid
ynthesis in platelets for their lifetimes and in nucleated
ells until more synthase can be made (8,9). Donating its
cetyl group allows aspirin to reduce thrombotic vascular
vents by 30%, deaths by 15% to 20% (10), and gastro-
ntestinal neoplasia by 40% to 50% (11).
Given the expectations at its synthesis, the astonishing
enefits of aspirin come at the ironical price of gastritis,
emorrhage, and a host of less common side effects—which
rings us to NO and an intriguing question. If adding an
cetyl residue made salicylate better, does adding a NO-
enerating residue make aspirin better? As though an
mmortal hand had framed this symmetry, the answer is
yes” (2). Nitric oxide is one of the great contributions of
0th-century vascular biology (3,12). It was discovered
ecause endothelium-derived relaxing factor (13) was not
rostacyclin (14,15). It is a ubiquitous signaler in both
he plant and animal kingdoms, and its biological activity is
emarkable, expansive, and complex (12). Nitric oxide
rotects the gastric mucosa, induces vasodilation, and
nhibits platelet aggregation, inflammation, cellular prolif-
ration, and apoptosis through both cyclic guanosine
onophosphate-dependent and -independent mechanisms
16).
There are tantalizing suggestions in experimental ani-
als, in well-conducted studies with NO-aspirin, about the
ontrol of hypertension (17,18), the reduction of brain
amage after stroke (19), and the inhibition of restenosis
fter percutaneous intervention (20). It also may be better
han aspirin alone in preventing or controlling colonic
denocarcinoma (21). Thus, it appears to have broad,
rotective properties against both cancer and atherosclerotic
ascular diseases and their complications.
Fiorucci and colleagues on both sides of the Atlantic
ave described much of the basic and clinical pharmacol-
gy of NO-aspirin. In their current work (2), they extend
revious observations to a 21-day trial of NCX-4016 in
omparison with aspirin in healthy subjects. Aspirin had
een synthesized to avoid the gastric irritation of salicylic
cid alone but was entirely unsuccessful. Nitric oxide-
spirin, at least during a period of three weeks, fixed what
nhibition of cyclooxygenase synthase made worse. The
uthors show convincingly that NO-aspirin alone causes
o gastroduodenal damage and that it significantly atten-
ates the damage done by co-administered aspirin at a
aily dose of 325 mg. At the same time, alone or in
ombination with aspirin, it inhibits platelet thrombox-
ne synthesis and aggregation. It does something, how-
ver, that aspirin does not do. In human monocytes, it
own-regulated tissue factor and markedly inhibited
nterleukin-6 and monocyte chemoattractant protein-1
xpression. Because atherogenesis and plaque rupture are
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August 4, 2004:642–3 Editorial Commentoints on the continuum of vascular inflammation, it is
easonable to speculate that long-term trials of NO-
spirin would best the parent compound in the primary
nd secondary prevention of vascular events.
The study leaves us with many questions, such as whether
n agent with such broad biologic properties, taken daily for
ife after the age of 45, might not have unexpected and
ndesirable effects. An equally important question relates to
he ideal dose of aspirin against which to compare this
heriac of nitrate. We still do not know (6,22). When the
nti-platelet trialists published their first article in 1988
10), they made it clear that nothing was to be gained from
igh doses of aspirin. Indeed, a dose of approximately 25
g, perhaps even lower, may be sufficient for prevention of
ascular events, and such a dose might lower gastrointestinal
nd hemorrhagic complications (6,10,22,23). We still do
ot know. However, most of the large, modern, multicenter
ardiovascular trials have used doses of 325 to 650 mg; so
he evidence favors standard doses, and before we rush to
educe the dose to nanograms as the homeopaths would
ave recommended, there also is the unexplored issue of
spirin resistance to resolve (24).
After six millennia of brewing and searching for a
niversal cure, the compounded pharmaceutical described as
O-aspirin may be nearly a theriac. But we must wait; the
rug is in Phase II clinical trials, and we will not know for
ome time whether it is an antidote to that which kills us.
nd who can say that the next versions, with a pinch of
tatin and eye of newt, will not be even better?
eprint requests and correspondence: Dr. Richard I. Levin,
YU School of Medicine, MSB-153, 550 First Avenue, New
ork, New York 10016. E-mail: richard.levin@med.nyu.edu.
igure 1. On the left is a three-dimensional rendering of aspirin or
cetylsalicylic acid. On the right is nitric oxide (NO)-aspirin (NCX-4016)
howing, from the left and moving clockwise, the aspirin group, a spacer
oined by an ester linkage, and the NO-releasing group. In vivo, esterases
eparate the aspirin moiety from the substituted benzene spacer-NO
omplex, and then NO is released slowly from the NO-releasing group
16). Images generated by T. Cardozo using ICM software (Molsoft LLC,
a Jolla, California).EFERENCES
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